Aim: Dyspnea is among symptoms that decrease quality of life for terminal cancer patients. There are few reports of the positive effects of oxycodone for the treatment of dyspnea, and no studies have focused on opioid-naïve patients. This study aimed to determine the efficacy and safety of continuous intravenous oxycodone infusion for opioid-naïve cancer patients with dyspnea. Methods: Eligible patients were opioid-naïve cancer inpatients who received continuous oxycodone infusion as a treatment for dyspnea under the care of the palliative care team at Komaki City Hospital between November 2013 and December 2016. We retrospectively investigated the improvement of dyspnea following continuous oxycodone infusion from the medical records. Results: This study included 19 patients, and the response rate to oxycodone infusion for dyspnea was 68.4%. Most participants were terminal cancer patients with performance status 3 or 4. Median survival of participants following continuous oxycodone infusion was 6 (range 1-377) days. No serious adverse events such as respiratory depression or somnolence were noted. Conclusion: Continuous oxycodone infusion could be a reasonable treatment option in the management of dyspnea in opioid-naïve cancer patients.
Introduction
Dyspnea is a commonly observed symptom in about 50-80% of patients with advanced cancer and one of the symptoms that decreases patients' quality of life (1, 2) . Morphine has been demonstrated in a randomized controlled trial and a systematic review as drug therapy for dyspnea in cancer patients, and it is widely used as a standard therapeutic agent (3, 4) . However, patients with renal dysfunction require careful attention during morphine administration because these patients can easily become drowsy or comatose due to accumulation of the active metabolites of morphine (5) .
Oxycodone, a semisynthetic opioid analgesic that is a μ-opioid receptor agonist, has also been reported to improve dyspnea in cancer patients (6, 7) . The 'Clinical guidelines for respiratory symptoms in cancer patients', issued by Japanese Society for Palliative Medicine, in Japan recommends oxycodone therapy for dyspnea as an alternative to morphine (8) . Oxycodone can be administered more safely than morphine to patients with renal dysfunction because they show less accumulation of pharmacologically active metabolites for oxycodone than for morphine (5) . However, the strength of the recommendation for oxycodone as a treatment for dyspnea in cancer patients is weak because of the low level of supporting evidence, comprising only a few case reports and an observational study (6) (7) (8) . Furthermore, opioid-naïve patients require careful administration of opioids compared with opioid-tolerant patients as they may be more likely to develop adverse events (9) (10) (11) .
To date, no studies have verified the effect of oxycodone on dyspnea in opioid-naïve cancer patients. Therefore, in this study, we retrospectively evaluated the efficacy and safety of continuous intravenous oxycodone infusion in opioid-naïve cancer patients with dyspnea.
Methods

Eligibility criteria
We reviewed cases in our database and retrospectively examined clinical data input between November 2013 and December 2016. Eligible participants were opioid-naïve cancer inpatients, over 20 years of age, who received continuous intravenous oxycodone infusion as a treatment for dyspnea under the care of the palliative care team at Komaki City Hospital, Aichi, Japan. We defined opioid naïve as the lack of use of opioid medication, including weak opioid and as-needed use of opioid drugs, within 1 month before hospital admission. Patients were excluded from the study if they could not be assessed because of impaired cognitive function. In addition, patients for whom medical treatment was initiated (removal of ascites or pleural effusion, administration of oxygen, benzodiazepine anxiolytic or steroid treatment intended to alleviate dyspnea) during the assessment period were excluded because we could not accurately assess the effectiveness of oxycodone. Patients who were administered oxygen continuously before continuous oxycodone infusion were allowed a change in supplemental oxygen dose.
The Institutional Review Board decided that this study would be exempted from the usual review process. Study approval was obtained from the President of Komaki City Hospital (approval no.: 171005).
Study procedures
Patients' baseline characteristics, including age, sex, duration of treatment from initial administration to death, initial and maximum doses of oxycodone (milligram per day) and administration period of oxycodone infusion, were retrospectively examined from electronic medical records. We investigated renal function [serum creatinine (Scr) and estimated glomerular filtration rate (eGFR)] and hepatic function [total bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] within 1 week of administration of continuous oxycodone infusion. eGFR was calculated as eGFR = 194 × Scr −1.094 × age −0.287 × 0.739.
We used a three-grade rating system based on previous reports assessing improvement in dyspnea (6): 0 = no or minimal effect, 1 = moderate effect and 2 = considerable effect with almost complete disappearance of symptoms. Minimal effect was defined as equivalent to no effect because it was sometimes difficult to discriminate mild from moderate by observer rating. Our palliative care team uses the Japanese version of the Support Team Assessment Schedule (STAS-J) to assess symptoms including dyspnea in clinical practice, particularly the subscale measuring how strongly patients are affected by their experience of symptoms (12) . The palliative care team staff and a nurse experienced in palliative care routinely assess effectiveness and adverse events. We investigated the STAS-J score for dyspnea and medical records for all patients and classified improvement in dyspnea following continuous oxycodone infusion according the three-grade rating and adverse events to oxycodone infusion. We defined the assessment period as 3 days after initiation of continuous oxycodone infusion because our palliative care team staff usually assess the effectiveness of oxycodone for dyspnea and other symptoms within this period. Furthermore, we defined the response rate to oxycodone infusion for dyspnea as the number of patients who achieved moderate or considerable effect divided by the number of patients for whom dyspnea could be measured. 
Results
Data from 24 patients were analyzed in this study ( Fig. 1 ). Among them, the effect of dyspnea could not be assessed in five patients; one underwent therapeutic thoracentesis at the same time as continuous oxycodone infusion and medical records were not available for the other four patients. Three of these four patients died within 2 days, and even though there was a possibility that the remaining patient would respond to treatment for dyspnea with continued administration of oxycodone infusion for 14 days, we classified the patient as an exclusion because the effectiveness of oxycodone for dyspnea had not been recorded in the electronic medical chart within 3 days after the starting continuous oxycodone infusion. None of the patients had impaired cognitive function at initiation of continuous oxycodone infusion or received anxiolytics or steroids during the assessment period. Some patients died within 3 days of oxycodone infusion. We assessed the effectiveness of oxycodone infusion for the treatment of dyspnea only when a moderate or considerable effect was recorded in the medical chart during the assessment period; we classified patients who could not be assessed based on the relief of dyspnea as exclusions. Patients' characteristics are shown in , respectively. Five patients (20.8%) had impaired hepatic function (AST and ALT > 100, total bilirubin >1.2 mg/dL).
Median survival duration following continuous oxycodone infusion was 6 (range 1-377) days. None of the patients experienced pain at the time of administering continuous oxycodone infusion.
The response rate to oxycodone infusion was 68.4% (Fig. 2) . Two patients achieved considerable dyspnea relief, 11 had moderate relief and 5 had a poor response or exacerbation. One patient changed to intravenous bolus oxycodone (2 mg each time) instead of continuous intravenous oxycodone infusion (6 mg per day) during the assessment period because the dyspnea was considerably relieved by bolus oxycodone.
The degree of dyspnea was classified in 15 patients using STAS-J. Although dyspnea severity was assessed using the STAS-J and NRS in many patients prior to administration of continuous oxycodone infusion, we could not assess the effectiveness of oxycodone for dyspnea using changes in these scores because only four patients had these values recorded in the electronic medical charts during the assessment period. Their dyspnea had been evaluated daily after oxycodone infusion, but their charts had not been updated correspondingly. Figure 3 shows the efficacy of continuous oxycodone infusion according to STAS-J. Continuous oxycodone infusion had a positive effect not only in patients with mild dyspnea but also in those with severe dyspnea.
The median initial and maintenance doses of oxycodone infusion were 6 (range 2-12) mg and 12 (range 0-24) mg, respectively ( Table 2 ). The median administration period of continuous oxycodone infusion was 4 (range 1-77) days (Fig. 4) .
Adverse events are shown in Table 3 . The main adverse event was somnolence; two of six patients stopped continuous oxycodone infusion due to somnolence. Two patients with a PS of four died within 2 days. The other patients had no serious adverse events due to continuous oxycodone infusion.
Discussion
In this first study to focus on the effectiveness of continuous oxycodone infusion for dyspnea in opioid-naïve patients, the response rate to continuous intravenous oxycodone infusion in opioid-naïve cancer patients who had dyspnea was 68.4%. Most of our patients were terminal cancer patients (PS 3-4), but no serious adverse events such as respiratory depression and sedation were noted.
Only one observational study has been reported in which oxycodone was effective in palliative treatment of dyspnea in cancer patients, and that study used compound continuous oxycodone infusion containing hydrocotarnine (Pavinal; Takeda Pharmaceutical Company, Osaka, Japan) and the participants were mostly opioid tolerant (6). They mainly had terminal disease and poor PS, as in our study, and the response rate of improvement in dyspnea was 88.6%. Therefore, we suggest that continuous oxycodone infusion is as effective as compound oxycodone for treating dyspnea in patients with terminal cancer.
It is often the case that terminal cancer patients show deterioration of organ function including renal function, so it is not easy to administer morphine in these patients. More than half of our patients had decreased renal function with eGFR <50 mL/min/1.73 m 2 before oxycodone administration, and there were some patients whose renal function might have deteriorated further during oxycodone administration. We observed that continuous oxycodone infusion led to improved symptoms in patients with severe dyspnea and poor PS. Thus, we believe that administration of continuous oxycodone infusion is an option for terminal cancer patients with dyspnea because it can be administered more safely than morphine in patients with renal dysfunction. However, further study is required to assess the administration of oxycodone in patients with renal dysfunction because no studies to date have compared efficacy and safety between oxycodone and morphine in terminally ill cancer patients with dyspnea. All opioid drugs were metabolized by the liver, so that they may influence on pharmacokinetic profile in patients with hepatic insufficiency (13) . It is difficult to conclude that it is better to use oxycodone than morphine for patients with liver dysfunction because there is no clear criterion for liver dysfunction that can be used as a guide for opioid dosing.
The optimal assessment period of continuous intravenous oxycodone infusion for dyspnea has not been clarified. We set the assessment period as 3 days after initiation of continuous oxycodone infusion because our palliative care team staff routinely assess effectiveness of oxycodone for dyspnea and other symptoms within 3 days after the start of oxycodone infusion. If we had set the assessment period as over 4 days, the patients would have been exposed to additional treatment for dyspnea such as oxygen therapy and administration of benzodiazepine receptor agonists. We thus consider 3 days after the start of oxycodone infusion to be an adequate assessment period in retrospective study.
Previous reports have suggested a wide range of appropriate opioid doses for dyspnea alleviation (14, 15) , but there has been no evidence regarding the use of morphine, oxycodone or fentanyl for treating dyspnea in opioid-naïve patients. It has also been reported Includes patients in whom improvement in dyspnea could not be assessed.
that cancer patients with dyspnea require a higher morphine dosage to treat pain (14) . However, most opioid-naïve patients were on low doses of continuous oxycodone infusion that were still effective for dyspnea, although this may have been affected by the large number of patients with renal dysfunction. Future studies are required to clarify the differences between opioid-tolerant and opioid-naïve patients with regard to the use of continuous oxycodone infusion for the treatment of dyspnea. The most common adverse event due to continuous oxycodone infusion was somnolence, and there was no evidence of serious adverse events in our study. We speculate that patients' general condition might have an effect on somnolence, because two patients who discontinued continuous oxycodone infusion due to somnolence died within 2 days. Opioid-naïve patients may have experienced few several adverse events due to low oxycodone dose in our study. From our results, we suggest that low-dose continuous oxycodone infusion might be a comparatively safe treatment for opioidnaïve cancer patients with terminal disease and has potential as a palliative treatment for dyspnea.
The limitations of this study include the retrospective design and small sample size. Further prospective studies with a larger sample size and multicenter design are needed. In addition, the individualized method of evaluating dyspnea used in this study implies that our results cannot be generalized. Moreover, STAS-J is a clinician proxy assessment tool that does not compare symptom severity between proxy-rated and patient-reported measures in designing the study protocol. Further clinical study will be needed with eligible patients and a standardized evaluation method of dyspnea.
In conclusion, continuous intravenous oxycodone infusion could be effective and safe for the treatment of dyspnea in opioid-naïve cancer patients. Continuous oxycodone infusion could be a reasonable alternative in the management of dyspnea in cancer patients.
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